Edition:
United States

Profile: OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

8.91USD
3:59pm EST
Change (% chg)

$0.18 (+2.06%)
Prev Close
$8.73
Open
$8.82
Day's High
$9.03
Day's Low
$8.78
Volume
34,280
Avg. Vol
58,606
52-wk High
$15.48
52-wk Low
$7.41

OncoMed Pharmaceuticals, Inc. (OncoMed), incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company's product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc.

Demcizumab (Anti-DLL4, OMP-21M18)

The Company's Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Demcizumab has a multi-pronged mechanism of action, including halting cancer stem cell growth and reducing cancer stem cell frequency, disrupting angiogenesis in the tumor, and augmenting anti-tumor immune responses by decreasing monocytic myeloid-derived suppressor cells (MDSCs). The Company is conducting a Phase II trial, known as DENALI, for demcizumab in combination with standard-of-care carboplatin and pemetrexed (Alimta) in non-small cell lung cancer, and a Phase II trial, known as YOSEMITE, for demcizumab in combination with standard-of-care gemcitabine and Abraxane in pancreatic cancer.

Tarextumab (Anti-Notch2/3, OMP-59R5)

Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Tarextumab antibody is a fully human antibody derived from phage display technology. Tarextumab is being tested in the Phase II portion of a Phase Ib/II clinical trial, known as PINNACLE (Phase Ib/II Investigation of anti-Notch Antibody therapy with platinum chemotherapy and etoposide in small cell Lung carcinoma Efficacy and safety), in previously untreated patients with extensive-stage small cell lung cancer.

Vantictumab (anti-Fzd7, OMP-18R5)

The Company's vantictumab product candidate is a fully human monoclonal antibody that modulates Wnt pathway signaling by binding to Frizzled receptors one, two, five, seven and eight. The Company has initiated three Phase Ib clinical trials in distinct solid tumor indications in combination with standard-of-care therapies, one trial in each of breast cancer, pancreatic cancer and non-small cell lung cancer (NSCLC).

Ipafricept (Fzd8-Fc, OMP-54F28)

Ipafricept is the Company's Wnt pathway modulator. Ipafricept is a fusion protein, or decoy receptor, containing part of the Frizzled8 receptor (Fzd8) fused to a human Immunoglobulin Fc domain. Ipafricept has shown evidence of anti-tumor activity in solid tumors, including pancreatic, breast, hepatocellular, ovarian, colorectal and other cancers, and reduction of CSC frequency in multiple preclinical models, either as a single agent or when combined with approved therapies. Ipafricept is in Phase Ib of clinical development.

Brontictuzumab (Anti-Notch1, OMP-52M51)

The Company's anti-Notch1 antibody, brontictuzumab, is a humanized monoclonal antibody. It is in Phase Ia of clinical development.

Anti-DLL4/VEGF Bispecific (OMP-305B83)

OMP-305B83 is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor (VEGF). The Company is enrolling patients with advanced solid tumors in a single-agent Phase Ia clinical trial.

Anti-RSPO3 (OMP-131R10)

Anti-RSPO3 is a monoclonal antibody. The Company is enrolling patients in a Phase Ia/b clinical trial. The Phase Ia portion of the anti-RSPO3 clinical trial is in solid tumor patients, and the Phase Ib portion of the clinical trial is in colorectal cancer in combination with standard-of-care folinic acid, fluorouracil and irinotecan (FOLFIRI) chemotherapy.

GITRL-Fc

GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein. GITRL-Fc product candidate is engineered using a single-gene linkerless GITRL trimer, which enables GITR activation and anti-tumor immune response.

The Company competes with AbbVie, Amgen, Astellas, AstraZeneca, Bayer Pharma AG, BMS, Celgene Corporation, Roche, GlaxoSmithKline LLC, Johnson & Johnson, Lilly, Merck, Merck Serono, Novartis, Prism Pharmaceuticals, Pfizer, Regeneron, Sanofi, Teva, Stemline Therapeutics, Inc. and Verastem, Inc.

Company Address

OncoMed Pharmaceuticals Inc

800 Chesapeake Dr
REDWOOD CITY   CA   94063-4748
P: +1650.9958200
F: +1650.2988600

Company Web Links